Genetic Technologies (ASX:GTG) Receivables Turnover: 0.00 (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Technologies Receivables Turnover?

Genetic Technologies ASX:GTG Receivables Turnover is 0.00 as of Jun. 2024.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genetic Technologies's Revenue for the three months ended in Jun. 2024 was A$0.00 Mil. Genetic Technologies's average Accounts Receivable for the three months ended in Jun. 2024 was A$0.21 Mil.

Genetic Technologies  (ASX:GTG) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Genetic Technologies Receivables Turnover Related Terms

Genetic Technologies Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies Receivables Turnover Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 1.89 25.59 27.40 38.23

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:GTG vs LDDD, NOTV, ATLN: Receivables Turnover Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies Receivables Turnover vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Receivables Turnover falls into.


Genetic Technologies Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Genetic Technologies's Receivables Turnover for the fiscal year that ended in Jun. 2024 is calculated as

Receivables Turnover (A: Jun. 2024 )
=Revenue / Average Accounts Receivable
=Revenue (A: Jun. 2024 ) / ((Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Jun. 2024 )) / count )
=7.665 / ((0.192 + 0.209) / 2 )
=7.665 / 0.2005
=38.23

Genetic Technologies's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

Receivables Turnover (Q: Jun. 2024 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2024 ) / ((Accounts Receivable (Q: Mar. 2024 ) + Accounts Receivable (Q: Jun. 2024 )) / count )
=0 / ((0 + 0.209) / 1 )
=0 / 0.209
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 0.00 mean?
Genetic Technologies (ASX:GTG) has a Receivables Turnover of 0.00 as of Jun. 2024. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' Receivables Turnover too high?
Genetic Technologies' current Receivables Turnover is 0.00.
How does Genetic Technologies' Receivables Turnover compare to LDDD and NOTV?
Genetic Technologies' Receivables Turnover of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Receivables Turnover is 5.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genetic Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Technologies's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current Receivables Turnover is 0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.